CheckMate 141: 1-Year Update and Subgroup Analysis of Nivolumab as First-Line Therapy in Patients with Recurrent/Metastatic Head and Neck Cancer

Maura L Gillison; George Blumenschein; Jerome Fayette; Joel Guigay; A Dimitrios Colevas; Lisa Licitra; Kevin J Harrington; Stefan Kasper; Everett E Vokes; Caroline Even; Francis Worden; Nabil F Saba; Lara Carmen Iglesias Docampo; Robert Haddad; Tamara Rordorf; Naomi Kiyota; Makoto Tahara; Manish Monga; Mark Lynch; Li Li; Robert L Ferris

doi:10.1634/theoncologist.2017-0674

CheckMate 141: 1-Year Update and Subgroup Analysis of Nivolumab as First-Line Therapy in Patients with Recurrent/Metastatic Head and Neck Cancer

Maura L Gillison, George Blumenschein, Jerome Fayette, Joel Guigay, A Dimitrios Colevas, Lisa Licitra, Kevin J Harrington, Stefan Kasper, Everett E Vokes, Caroline Even, Francis Worden, Nabil F Saba, Lara Carmen Iglesias Docampo, Robert Haddad, Tamara Rordorf, Naomi Kiyota, Makoto Tahara, Manish Monga, Mark Lynch, Li LiRobert L Ferris

Fondazione IRCCS Istituto Nazionale dei Tumori

Research output: Contribution to journal › Article › peer-review

Abstract

Nivolumab significantly improved overall survival (OS) vs investigator's choice (IC) of chemotherapy at the primary analysis of randomized, open-label, phase 3 CheckMate 141 in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN). Here, we report that OS benefit with nivolumab was maintained at a minimum follow-up of 11.4 months. Further, OS benefit with nivolumab vs IC was also noted among patients who received first-line treatment for R/M SCCHN after progressing on platinum therapy for locally advanced disease in the adjuvant or primary (i.e., with radiation) setting.

Original language	English
Pages (from-to)	1079-1082
Number of pages	4
Journal	The oncologist
Volume	23
Issue number	9
DOIs	https://doi.org/10.1634/theoncologist.2017-0674
Publication status	Published - Sep 2018

Access to Document

10.1634/theoncologist.2017-0674

Fingerprint Dive into the research topics of 'CheckMate 141: 1-Year Update and Subgroup Analysis of Nivolumab as First-Line Therapy in Patients with Recurrent/Metastatic Head and Neck Cancer'. Together they form a unique fingerprint.

Cite this

Gillison, M. L., Blumenschein, G., Fayette, J., Guigay, J., Colevas, A. D., Licitra, L., Harrington, K. J., Kasper, S., Vokes, E. E., Even, C., Worden, F., Saba, N. F., Iglesias Docampo, L. C., Haddad, R., Rordorf, T., Kiyota, N., Tahara, M., Monga, M., Lynch, M., ... Ferris, R. L. (2018). CheckMate 141: 1-Year Update and Subgroup Analysis of Nivolumab as First-Line Therapy in Patients with Recurrent/Metastatic Head and Neck Cancer. The oncologist, 23(9), 1079-1082. https://doi.org/10.1634/theoncologist.2017-0674

CheckMate 141 : 1-Year Update and Subgroup Analysis of Nivolumab as First-Line Therapy in Patients with Recurrent/Metastatic Head and Neck Cancer. / Gillison, Maura L; Blumenschein, George; Fayette, Jerome; Guigay, Joel; Colevas, A Dimitrios; Licitra, Lisa; Harrington, Kevin J; Kasper, Stefan; Vokes, Everett E; Even, Caroline; Worden, Francis; Saba, Nabil F; Iglesias Docampo, Lara Carmen; Haddad, Robert; Rordorf, Tamara; Kiyota, Naomi; Tahara, Makoto; Monga, Manish; Lynch, Mark; Li, Li; Ferris, Robert L.

In: The oncologist, Vol. 23, No. 9, 09.2018, p. 1079-1082.

Research output: Contribution to journal › Article › peer-review

Gillison, ML, Blumenschein, G, Fayette, J, Guigay, J, Colevas, AD, Licitra, L, Harrington, KJ, Kasper, S, Vokes, EE, Even, C, Worden, F, Saba, NF, Iglesias Docampo, LC, Haddad, R, Rordorf, T, Kiyota, N, Tahara, M, Monga, M, Lynch, M, Li, L & Ferris, RL 2018, 'CheckMate 141: 1-Year Update and Subgroup Analysis of Nivolumab as First-Line Therapy in Patients with Recurrent/Metastatic Head and Neck Cancer', The oncologist, vol. 23, no. 9, pp. 1079-1082. https://doi.org/10.1634/theoncologist.2017-0674

Gillison, Maura L ; Blumenschein, George ; Fayette, Jerome ; Guigay, Joel ; Colevas, A Dimitrios ; Licitra, Lisa ; Harrington, Kevin J ; Kasper, Stefan ; Vokes, Everett E ; Even, Caroline ; Worden, Francis ; Saba, Nabil F ; Iglesias Docampo, Lara Carmen ; Haddad, Robert ; Rordorf, Tamara ; Kiyota, Naomi ; Tahara, Makoto ; Monga, Manish ; Lynch, Mark ; Li, Li ; Ferris, Robert L. / CheckMate 141 : 1-Year Update and Subgroup Analysis of Nivolumab as First-Line Therapy in Patients with Recurrent/Metastatic Head and Neck Cancer. In: The oncologist. 2018 ; Vol. 23, No. 9. pp. 1079-1082.

@article{feee0359427748a898a07c0d98c03661,

title = "CheckMate 141: 1-Year Update and Subgroup Analysis of Nivolumab as First-Line Therapy in Patients with Recurrent/Metastatic Head and Neck Cancer",

abstract = "Nivolumab significantly improved overall survival (OS) vs investigator's choice (IC) of chemotherapy at the primary analysis of randomized, open-label, phase 3 CheckMate 141 in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN). Here, we report that OS benefit with nivolumab was maintained at a minimum follow-up of 11.4 months. Further, OS benefit with nivolumab vs IC was also noted among patients who received first-line treatment for R/M SCCHN after progressing on platinum therapy for locally advanced disease in the adjuvant or primary (i.e., with radiation) setting.",

author = "Gillison, {Maura L} and George Blumenschein and Jerome Fayette and Joel Guigay and Colevas, {A Dimitrios} and Lisa Licitra and Harrington, {Kevin J} and Stefan Kasper and Vokes, {Everett E} and Caroline Even and Francis Worden and Saba, {Nabil F} and {Iglesias Docampo}, {Lara Carmen} and Robert Haddad and Tamara Rordorf and Naomi Kiyota and Makoto Tahara and Manish Monga and Mark Lynch and Li Li and Ferris, {Robert L}",

note = "{\textcopyright} AlphaMed Press 2018.",

year = "2018",

month = sep,

doi = "10.1634/theoncologist.2017-0674",

language = "English",

volume = "23",

pages = "1079--1082",

journal = "Oncologist",

issn = "1083-7159",

publisher = "Wiley Blackwell",

number = "9",

}

TY - JOUR

T1 - CheckMate 141

T2 - 1-Year Update and Subgroup Analysis of Nivolumab as First-Line Therapy in Patients with Recurrent/Metastatic Head and Neck Cancer

AU - Gillison, Maura L

AU - Blumenschein, George

AU - Fayette, Jerome

AU - Guigay, Joel

AU - Colevas, A Dimitrios

AU - Licitra, Lisa

AU - Harrington, Kevin J

AU - Kasper, Stefan

AU - Vokes, Everett E

AU - Even, Caroline

AU - Worden, Francis

AU - Saba, Nabil F

AU - Iglesias Docampo, Lara Carmen

AU - Haddad, Robert

AU - Rordorf, Tamara

AU - Kiyota, Naomi

AU - Tahara, Makoto

AU - Monga, Manish

AU - Lynch, Mark

AU - Li, Li

AU - Ferris, Robert L

PY - 2018/9

Y1 - 2018/9

N2 - Nivolumab significantly improved overall survival (OS) vs investigator's choice (IC) of chemotherapy at the primary analysis of randomized, open-label, phase 3 CheckMate 141 in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN). Here, we report that OS benefit with nivolumab was maintained at a minimum follow-up of 11.4 months. Further, OS benefit with nivolumab vs IC was also noted among patients who received first-line treatment for R/M SCCHN after progressing on platinum therapy for locally advanced disease in the adjuvant or primary (i.e., with radiation) setting.

AB - Nivolumab significantly improved overall survival (OS) vs investigator's choice (IC) of chemotherapy at the primary analysis of randomized, open-label, phase 3 CheckMate 141 in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN). Here, we report that OS benefit with nivolumab was maintained at a minimum follow-up of 11.4 months. Further, OS benefit with nivolumab vs IC was also noted among patients who received first-line treatment for R/M SCCHN after progressing on platinum therapy for locally advanced disease in the adjuvant or primary (i.e., with radiation) setting.

U2 - 10.1634/theoncologist.2017-0674

DO - 10.1634/theoncologist.2017-0674

M3 - Article

C2 - 29866947

VL - 23

SP - 1079

EP - 1082

JO - Oncologist

JF - Oncologist

SN - 1083-7159

IS - 9

ER -